1. Pink Sheet

Pharma Exhales, Dodges Financial Blow With Tariff Exemption

 
• By Jessica Merrill

Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.

Tariffs still could be added to pharmaceuticals later, analysts cautioned. (Shutterstock)
Key Takeaways
  • Pharmaceuticals are not subject to President Trump’s sweeping tariffs on most goods imported into the US, a reprieve for industry.
  • The situation remains fluid and tariffs still could be added to pharmaceuticals at a later date, some analysts cautioned.
  • Macroeconomic uncertainty caused by tariffs across sectors is expected to be an overhang on the high-risk area of drug development.

President Donald Trump’s remarks were not immediately clear, but it appears pharmaceuticals are exempt from a sweeping US tariff plan that targets almost all other goods and most American trading...

The executive order that Trump outlined on 2 April exempted a few products from the tariffs, including “copper, pharmaceuticals, semiconductors, lumber articles, certain critical minerals, and energy products.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.